全文获取类型
收费全文 | 2630篇 |
免费 | 236篇 |
国内免费 | 162篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 37篇 |
妇产科学 | 67篇 |
基础医学 | 301篇 |
口腔科学 | 26篇 |
临床医学 | 232篇 |
内科学 | 609篇 |
皮肤病学 | 18篇 |
神经病学 | 295篇 |
特种医学 | 34篇 |
外科学 | 242篇 |
综合类 | 120篇 |
预防医学 | 184篇 |
眼科学 | 12篇 |
药学 | 223篇 |
中国医学 | 14篇 |
肿瘤学 | 603篇 |
出版年
2023年 | 58篇 |
2022年 | 142篇 |
2021年 | 228篇 |
2020年 | 230篇 |
2019年 | 231篇 |
2018年 | 224篇 |
2017年 | 154篇 |
2016年 | 187篇 |
2015年 | 152篇 |
2014年 | 335篇 |
2013年 | 218篇 |
2012年 | 162篇 |
2011年 | 170篇 |
2010年 | 95篇 |
2009年 | 104篇 |
2008年 | 101篇 |
2007年 | 62篇 |
2006年 | 46篇 |
2005年 | 38篇 |
2004年 | 23篇 |
2003年 | 11篇 |
2002年 | 6篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 7篇 |
1998年 | 3篇 |
1997年 | 12篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1990年 | 1篇 |
排序方式: 共有3028条查询结果,搜索用时 468 毫秒
31.
Jawaher Abdullah Alamoudi Wenkuan Li Nagsen Gautam Marco Olivera Jane Meza Sandeep Mukherjee Yazen Alnouti 《World journal of hepatology》2021,13(4):433-455
BACKGROUNDHepatobiliary diseases result in the accumulation of toxic bile acids (BA) in the liver, blood, and other tissues which may contribute to an unfavorable prognosis.AIMTo discover and validate diagnostic biomarkers of cholestatic liver diseases based on the urinary BA profile.METHODSWe analyzed urine samples by liquid chromatography-tandem mass spectrometry and compared the urinary BA profile between 300 patients with hepatobiliary diseases vs 103 healthy controls by statistical analysis. The BA profile was characterized using BA indices, which quantifies the composition, metabolism, hydrophilicity, and toxicity of the BA profile. BA indices have much lower inter- and intra-individual variability compared to absolute concentrations of BA. In addition, BA indices demonstrate high area under the receiver operating characteristic curves, and changes of BA indices are associated with the risk of having a liver disease, which demonstrates their use as diagnostic biomarkers for cholestatic liver diseases.RESULTSTotal and individual BA concentrations were higher in all patients. The percentage of secondary BA (lithocholic acid and deoxycholic acid) was significantly lower, while the percentage of primary BA (chenodeoxycholic acid, cholic acid, and hyocholic acid) was markedly higher in patients compared to controls. In addition, the percentage of taurine-amidation was higher in patients than controls. The increase in the non-12α-OH BA was more profound than 12α-OH BA (cholic acid and deoxycholic acid) causing a decrease in the 12α-OH/ non-12α-OH ratio in patients. This trend was stronger in patients with more advanced liver diseases as reflected by the model for end-stage liver disease score and the presence of hepatic decompensation. The percentage of sulfation was also higher in patients with more severe forms of liver diseases.CONCLUSIONBA indices have much lower inter- and intra-individual variability compared to absolute BA concentrations and changes of BA indices are associated with the risk of developing liver diseases. 相似文献
32.
Qingshu Lu Shein Chung Chow Yunchan Chi Lan Yan Yang 《Journal of biopharmaceutical statistics》2013,23(2):311-323
In clinical development, an adaptive design combining results from two separate studies (e.g., a seamless adaptive design with a dose finding study phase and a confirmatory study phase) is commonly considered. The purpose of an adaptive design is not only to reduce lead time between the two studies, but also to evaluate the treatment effect in a more efficient way. In this paper, the focus is on the case where the study objectives are the same but the time durations of the study periods are different in the two stages. In particular, event data are collected in both stages. Statistical procedure for combining data observed from the two different stages is discussed. Furthermore, results on hypotheses testing and sample size calculation are derived for the comparison of two treatments. 相似文献
33.
《药学学报(英文版)》2017,7(5):564-570
Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human epidermoid carcinoma cell line, KB/ATO, from its parental KB-3-1 cells. In addition to ATO, KB/ATO cells also exhibited cross-resistance to other anticancer drugs such as cisplatin, antimony potassium tartrate, and 6-mercaptopurine. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells. Further analysis indicated that neither application of P-glycoprotein inhibitor, breast cancer resistant protein (BCRP) inhibitor, or multidrug resistance protein 1 (MRP1) inhibitor could eliminate ATO resistance. We found that the expression level of ABCB6 was increased in KB/ATO cells. In conclusion, ABCB6 could be an important factor for ATO resistance in KB/ATO cells. The ABCB6 level may serve as a predictive biomarker for the effectiveness of ATO therapy. 相似文献
34.
外周血miRNA的诊断意义 总被引:1,自引:0,他引:1
micro RNAs是一类广泛存在于真核细胞中的长约22个核苷酸的非编码RNA分子。外周血miRNA与生长发育及妊娠等生理现象的改变密切相关,在疾病的诊断、鉴别诊断、预后判断以及法医鉴定等方面发挥着重要作用。 相似文献
35.
36.
MicroRNAs (miRNAs) have become one of the hottest topics in biology over recent years, but remarkably have only been formally recognized for just over 10 years. These endogenously produced short (19–24 nt) non-coding RNAs have introduced an entirely new paradigm in our understanding of gene control and it is now evident that miRNAs play a crucial regulatory role in many, if not all, physiological and pathological processes. In this review we provide an overview of the role and potential clinical utility for miRNAs in hematological malignancies and their function in normal hematopoiesis. Although still in its infancy, the miRNA field has already added much to our understanding of hematological processes, and provides us with novel tools as both biomarkers and therapeutic agents for hematological malignancies. 相似文献
37.
38.
David Leong Rajat Rai Brandon Nguyen Andrew Lee Desmond Yip 《World journal of clinical oncology》2014,5(4):633-645
Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies. 相似文献
39.
《The surgeon》2021,19(6):e536-e548
IntroductionParathyroid cancers are rare and difficult to distinguish from benign parathyroid tumours. Prediction of malignancy often relies on intraoperative assessment of invasion. Standard histology is also inadequate; especially in the absence of local invasion, lymph nodal disease and metastasis. The aim of this project was to systematically review published literature on potential bio-markers used for the diagnosis of parathyroid cancer.MethodsPubmed, Web of Science and Medline databases were searched. Inclusion criteria included English language papers published after 1985 and reporting on biomarkers in human studies of parathyroid cancer and benign disease.Results118 relevant papers were appraised; all were observational studies. At least 2 papers studied 8 serum, 4 urine and 27 tissue biomarkers on the diagnosis of parathyroid cancer. Of these, 5 serum and 13 tissue markers have been demonstrated in at least one study to be statistically different in benign and malignant disease. We present a synthesis of data for each biomarker and measures of diagnostic accuracy where possible.ConclusionsConsideration should be given to the use of a panel of biomarkers to review patients with suspected parathyroid cancer. A profile including serum calcium and PTH levels and tissue expression of APC, Parafibromin, PGP9.5, Galectin 3 and Ki67 is proposed.Systematic Review Registration Number – CRD42019127833. 相似文献
40.
Evaluation of Full-length,Cleaved and Nitrosylated Serum Surfactant Protein D as Biomarkers for COPD
《COPD》2013,10(2):79-95
Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is characterized by partially reversible airflow obstruction. Serum surfactant protein D (SP-D) is synthesized by type II pneumocytes and Clara cells and participates in surfactant homeostasis and pulmonary host defense. Serum levels of SP-D are raised in individuals with COPD but there is no correlation between the serum level of SP-D and the severity of airflow obstruction. Serum SP-D is present in different forms that may have more utility as a biomarker for COPD. We report here the development of new monoclonal antibodies to full length and cleaved SP-D. We have assessed these and existing antibodies in 98 individuals with COPD recruited to the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Our data show that neither monoclonal antibodies to full length nor cleaved SP-D provide additional information over that obtained with a polyclonal antibody. Moreover, levels of serum nitrosylated-SP-D did not correlate with serum level of SP-D or any clinical phenotype of COPD. The measurement of modified SP-D is of limited value in characterising individuals with COPD. 相似文献